Observational studyBMC infectious diseases2025
Epidemiology, clinical characteristics, and outcome in candidemia: a retrospective five-year analysis from two tertiary general hospitals.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Pneumonia Etiology and Risk Factors in a Tertiary Hospital During the COVID-19 Era: A Retrospective Analysis (2020-2024).Journal of general internal medicine · 2026Article
- Global surveillance ofAntimicrobial agents and chemotherapy · 2026Article
- Retrospective analysis of the epidemiological characteristics, risk factors, survival rate, and drug resistance of candidemia and construction of a logistic regression prediction model (2013-2024).BMC infectious diseases · 2026Article
- Clinical Determinants of 30-Day Mortality in Candidemia: Antifungal Susceptibility and Treatment Patterns in a 10-Year Cohort.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical characteristics and risk factors of mortality in patients with candidemia: a four-year retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Epidemiology, risk factors, and mortality of Candida bloodstream infection in Yulin, China: a 7-year retrospective study.BMC infectious diseases · 2026Article
- Evaluation of an Antifungal Agent Against Nakaseomyces Glabratus in the in Vivo Model Galleria Mellonella.Current microbiology · 2026Article
- Epidemiological Characteristics and Mortality Predictors of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2025Article
- Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Pathogens (Basel, Switzerland) · 2025Review
- Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCandidemia is linked with high mortality, highlighting the critical importance of timely empirical antimicrobial therapy and precise medical intervention before a definite etiologic diagnosis. The current study aimed to investigate the prevalence of pathogens in patients with candidemia and evaluate the potential independent risk factors for Candida albicans bloodstream infections (BSI), as well as the prognosis of candidemia.
methodsA retrospective bicentric observational study was performed, incorporating 132 candidemia episodes from two tertiary general hospitals in the Linyi area between January 2019 and December 2023. Data on demographic characteristics, underlying diseases, medical intervention, and antimicrobial sensitivity were collected and analyzed using SPSS version 27.0. Univariate analysis and binary logistic regression analyses were performed to identify risk factors for non-albicans Candida infections and candidemia-related mortality.
resultsA total of 132 strains of Candida species were isolated from 132 patients with candidemia, with non-albicans Candida accounting for 71.97% (95/132) and Candida albicans for 28.03%. Although Candida albicans remains the predominant species, the proportion of Candida tropicalis, mainly from the Hematology Ward, is approaching that of Candida albicans, which was mainly found in the intensive care unit (ICU) (27.27% versus 28.03%). Moreover, Candida tropicalis, the most frequently isolated non-albicans Candida species, exhibited poorer sensitivity to triazole drugs than other Candida species. Multivariate analysis identified gastrointestinal surgery (non-tumor) as an independent risk factor for Candida albicans BSI (odds ratio [OR] = 6.683, 95% confidence interval [CI]: 1.253-35.632, P = 0.026). The 30-day mortality rate of candidemia in the current study was 30.3%. Binary logistic regression analysis identified several factors significantly associated with mortality, including age (OR = 1.038, 95% CI: 1.007-1.071, P = 0.018) and septic shock (OR = 3.307, 95% CI: 1.205-9.071, P = 0.020).
conclusionThe mortality rate of candidemia in the current study reached 30.3%, indicating a high disease burden. Recently, the proportion of non-albicans Candida, especially Candida tropicalis, has increased markedly. Therefore, increased attention should be given to patients with the identified risk factors to improve candidemia management and outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.